Literature DB >> 21901316

Acute and post-acute behavioral and psychological effects of salvinorin A in humans.

Peter H Addy1.   

Abstract

RATIONALE: Salvia divinorum has been used for centuries, and nontraditional use in modern societies is increasing. Inebriation and aftereffects of use are poorly documented in the scientific literature.
OBJECTIVES: This double-blind, placebo-controlled, randomized study analyzed subjective experiences of salvinorin A (SA) inebriation and consequences of use after 8 weeks.
METHODS: Thirty middle-aged, well-educated, hallucinogen-experienced participants smoked either 1,017 or 100 μg SA 2 weeks apart in counterbalanced order. Vital signs were recorded before and after inhalation. A researcher rated participants' behavior during sessions. Participants completed the Hallucinogen Rating Scale (HRS) assessing inebriation immediately after each session. Differences were analyzed between groups as functions of dose and time. After 8 weeks, participants were interviewed to determine reported consequences and aftereffects.
RESULTS: Participants talked, laughed, and moved more often on an active dose. All six HRS clusters were significantly elevated on an active dose indicating hallucinogenic experiences. No significant adverse events were observed or reported by participants.
CONCLUSIONS: The present results indicate similarities as well as differences between the subjective effects of S. divinorum and other hallucinogens. As a selective kappa opioid receptor agonist, SA may be useful for expanding understanding of the psychopharmacology and psychology of hallucinogenic states beyond serotonergic mechanisms.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21901316     DOI: 10.1007/s00213-011-2470-6

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  32 in total

1.  Analysis of the psychoactive terpenoid salvinorin A content in five Salvia divinorum herbal products.

Authors:  William R Wolowich; Alisha M Perkins; John J Cienki
Journal:  Pharmacotherapy       Date:  2006-09       Impact factor: 4.705

2.  Enadoline, a selective kappa opioid agonist: comparison with butorphanol and hydromorphone in humans.

Authors:  S L Walsh; E C Strain; M E Abreu; G E Bigelow
Journal:  Psychopharmacology (Berl)       Date:  2001-09       Impact factor: 4.530

3.  Psychedelic effects of ketamine in healthy volunteers: relationship to steady-state plasma concentrations.

Authors:  T A Bowdle; A D Radant; D S Cowley; E D Kharasch; R J Strassman; P P Roy-Byrne
Journal:  Anesthesiology       Date:  1998-01       Impact factor: 7.892

4.  Salvinorin A fails to substitute for the discriminative stimulus effects of LSD or ketamine in Sprague-Dawley rats.

Authors:  Bryan A Killinger; Mary M Peet; Lisa E Baker
Journal:  Pharmacol Biochem Behav       Date:  2010-05-20       Impact factor: 3.533

5.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys.

Authors:  Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-11-09       Impact factor: 4.030

6.  Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.

Authors:  R J Strassman; C R Qualls; E H Uhlenhuth; R Kellner
Journal:  Arch Gen Psychiatry       Date:  1994-02

7.  Determination of salvinorin A and salvinorin B in Salvia divinorum-related products circulated in Japan.

Authors:  Kenji Tsujikawa; Kenji Kuwayama; Hajime Miyaguchi; Tatsuyuki Kanamori; Yuko T Iwata; Takemi Yoshida; Hiroyuki Inoue
Journal:  Forensic Sci Int       Date:  2008-09-02       Impact factor: 2.395

8.  Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.

Authors:  Lisa E Baker; John J Panos; Bryan A Killinger; Mary M Peet; Lisa M Bell; Larissa A Haliw; Sheryl L Walker
Journal:  Psychopharmacology (Berl)       Date:  2009-01-20       Impact factor: 4.530

9.  The plant-derived hallucinogen, salvinorin A, produces kappa-opioid agonist-like discriminative effects in rhesus monkeys.

Authors:  Eduardo R Butelman; Todd J Harris; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2003-10-30       Impact factor: 4.530

10.  Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial.

Authors:  John E Mendelson; Jeremy R Coyle; Juan Carlos Lopez; Matthew J Baggott; Keith Flower; E Thomas Everhart; Thomas A Munro; Gantt P Galloway; Bruce M Cohen
Journal:  Psychopharmacology (Berl)       Date:  2010-12-08       Impact factor: 4.530

View more
  25 in total

1.  Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction.

Authors:  Albert Garcia-Romeu; Roland R Griffiths; Matthew W Johnson
Journal:  Curr Drug Abuse Rev       Date:  2014

2.  Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist Salvinorin A in humans.

Authors:  Mohini Ranganathan; Ashley Schnakenberg; Patrick D Skosnik; Bruce M Cohen; Brian Pittman; R Andrew Sewell; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2012-07-18       Impact factor: 13.382

Review 3.  Clinical applications of hallucinogens: A review.

Authors:  Albert Garcia-Romeu; Brennan Kersgaard; Peter H Addy
Journal:  Exp Clin Psychopharmacol       Date:  2016-08       Impact factor: 3.157

4.  Behavioural and neurochemical assessment of salvinorin A abuse potential in the rat.

Authors:  Veronica Serra; Liana Fattore; Maria Scherma; Roberto Collu; Maria Sabrina Spano; Walter Fratta; Paola Fadda
Journal:  Psychopharmacology (Berl)       Date:  2014-06-13       Impact factor: 4.530

5.  Effects of the psychotomimetic benzomorphan N-allylnormetazocine (SKF 10,047) on prepulse inhibition of startle in mice.

Authors:  Adam L Halberstadt; James Hyun; Michael A Ruderman; Susan B Powell
Journal:  Pharmacol Biochem Behav       Date:  2016-05-26       Impact factor: 3.533

6.  High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens.

Authors:  Chad J Reissig; Lawrence P Carter; Matthew W Johnson; Miriam Z Mintzer; Margaret A Klinedinst; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2012-04-13       Impact factor: 4.530

Review 7.  The Kappa Opioid Receptor: A Promising Therapeutic Target for Multiple Pathologies.

Authors:  Martin L Dalefield; Brittany Scouller; Rabia Bibi; Bronwyn M Kivell
Journal:  Front Pharmacol       Date:  2022-06-20       Impact factor: 5.988

8.  Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans.

Authors:  Matthew W Johnson; Katherine A MacLean; Michael J Caspers; Thomas E Prisinzano; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-02-15       Impact factor: 4.153

9.  Abuse and Effects of Salvia divinorum in a Sample of Patients Hospitalized for Substance Dependence.

Authors:  Antoine Karam; Aida Said; Chafika Assaad; Souheil Hallit; Georges Haddad; Dory Hachem; Francois Kazour
Journal:  Community Ment Health J       Date:  2018-10-29

10.  Dose-related effects of salvinorin A in humans: dissociative, hallucinogenic, and memory effects.

Authors:  Katherine A MacLean; Matthew W Johnson; Chad J Reissig; Thomas E Prisinzano; Roland R Griffiths
Journal:  Psychopharmacology (Berl)       Date:  2012-11-08       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.